Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 5
Submit an article Journal homepage
129
Views
22
CrossRef citations to date
0
Altmetric
Drug Evaluation

Vernakalant – a promising therapy for conversion of recent-onset atrial fibrillation

Gerald V Naccarelli Penn State University College of Medicine, Division of Cardiology, 500 University Dr Room H 1.511, Hershey, PA 17033, USA +1 717 531 3907; +1 717 531 4077; [email protected]
, MD,
Deborah L Wolbrette Penn State University College of Medicine, Division of Cardiology, 500 University Dr Room H 1.511, Hershey, PA 17033, USA +1 717 531 3907; +1 717 531 4077; [email protected]
, MD,
Soraya Samii Penn State University College of Medicine, Division of Cardiology, 500 University Dr Room H 1.511, Hershey, PA 17033, USA +1 717 531 3907; +1 717 531 4077; [email protected]
, MD PhD,
Javier E Banchs Penn State University College of Medicine, Division of Cardiology, 500 University Dr Room H 1.511, Hershey, PA 17033, USA +1 717 531 3907; +1 717 531 4077; [email protected]
, MD,
Erica Penny-Peterson Penn State University College of Medicine, Division of Cardiology, 500 University Dr Room H 1.511, Hershey, PA 17033, USA +1 717 531 3907; +1 717 531 4077; [email protected]
, MD,
Robert Stevenson Penn State University College of Medicine, Division of Cardiology, 500 University Dr Room H 1.511, Hershey, PA 17033, USA +1 717 531 3907; +1 717 531 4077; [email protected]
, MD &
Mario D Gonzalez Penn State University College of Medicine, Division of Cardiology, 500 University Dr Room H 1.511, Hershey, PA 17033, USA +1 717 531 3907; +1 717 531 4077; [email protected]
, MD show all
Pages 805-810 | Published online: 30 Apr 2008

Bibliography

  • Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 2003;91:15D-26D
  • Daoud EG. Percutaneous catheter ablation of atrial fibrillation. Expert Rev Cardiovasc Ther 2007;59:693-705
  • Choudhury A, Lip GY. Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utility. Expert Opin Investig Drug 2004;13:841-55
  • Naccarelli GV, Wolbrette, Samii S, et al. New antiarrhythmic treatment of atrial fibrillation. Expert Rev Cardiovasc Ther 2007;5:707-14
  • Fedida D, Orth P, Chen J, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 2006;16:1227-38
  • Roy D, Rowe BH, Stiell IG, et al. for the CRAFT Investigators. A randomized, controlled trial of RSD 1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004;44:2355-61
  • Fedida D. Vernakalant (RSD1235): a novel, atrial selective antifibrillatory agent. Expert Opin Investig Drugs 2007;16:519-32
  • Dia EQ, Rathbun RA, Song JC. Vernakalant: a novel antiarrhythmic agent for the treatment of atrial fibrillation. Formulary 2007;42:475-83
  • Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic therapy. Nat Rev Drug Discov 2006;5:1034-49
  • Orth PMR, Hesketh JC, Mak CKH, et al. RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res 2006;70:486-96
  • Fedida D, Orth PMR, Hesketh JC, Ezrin AM. The role of the late INa and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. J Cardiovasc Electrophysiol 2006;17:S71-8
  • Dorian P, Pinter A, Mangat I, et al. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent on atrial electrophysiology in humans. J Cardiovasc Pharmacol 2007;50:35-40
  • Roy D, Pratt C, Wyse DG, et al. RSD1235 for conversion of atrial fibrillation. The phase III Atrial Arrhythmia Conversion Trial. Presented at the Heart Rhythm Society 2005 26th Annual Scientific Sessions; New Orleans, LA, USA; 2005
  • Pratt C, Roy D, Juul-Moller S, et al. Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: results of a phase III, randomized, placebo-controlled, multicenter trial [abstract 47]. J Am Coll Cardiol 2006;10A
  • Pratt CM, Navratil J, Nagy A, et al. Oral vernakalant (RSD1235-SR) prevents recurrence of atrial fibrillation following cardioversion [abstract 4]. Heart Rhythm 2007;S176
  • Roy D, Pratt C, Camm AJ, et al. RSD1235 effectively converts atrial fibrillation to sinus rhythm independent of background use of oral rate- or rhythm-control medications [abstract 114]. Circulation 2006;II-790
  • Kowey PR, Roy D, Pratt CM, et al. Efficacy and safety of vernakalant hydrochloride injection for the treatment of atrial fibrillation after valvular or coronary artery bypass surgery [abstract 16]. Circulation 2007;II-636
  • Astellas Pharma US, Inc. Briefing materials for the cardiovascular and renal drugs advisory committee: December 11, 2007 – Kynapid™ (vernakalant hydrochloride injection). NDA 22-034

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.